BridgeBio Pharma, Inc. (BBIO)
66.61
-1.12
(-1.65%)
USD |
NASDAQ |
May 27, 15:48
BridgeBio Pharma Cash from Investing (Quarterly) : -42.74M for March 31, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Pfizer Inc. | 785.00M |
| Alnylam Pharmaceuticals, Inc. | -25.54M |
| Ionis Pharmaceuticals, Inc. | 536.82M |
| BioMarin Pharmaceutical, Inc. | 725.53M |
| Cytokinetics, Inc. | 145.49M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -197.28M |
| Cash from Financing (Quarterly) | 549.89M |
| Free Cash Flow | -452.02M |
| Free Cash Flow Per Share (Quarterly) | -1.013 |
| Free Cash Flow to Equity (Quarterly) | -853.51M |
| Free Cash Flow to Firm (Quarterly) | -144.53M |
| Free Cash Flow Yield | -3.52% |